Targovax promotes new CFO

pharmafile | January 6, 2017 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Targovax 

Erik Digman Wiklund has been named as the new chief financial officer (CFO) of Norwegian biotech Targovax, replacing Oystein Soug who became the company’s new CEO in November last year. He will take up the role in April.

Wiklund previously served as director of product innovation at nutraceutical company Aker Biomarine Antarctic AS, and at cancer biotech Algeta ASA before that. He brings a wealth of management consulting experience garnered during his tenure at the Pharma & Health Care practice at McKinsey & Company.

His predecessor Soug remarked: “We are delighted to announce the appointment of Erik as our new CFO. He has an impressive track record in commercial and operational roles in the biotechnology industry, combined with a strong scientific background. Erik’s breadth of expertise will be key as we approach a number of important milestones in 2017 and 2018 within our innovative clinical pipeline, designed to help patients own immune system to fight cancer.”

Related Content

No items found

Latest content